Overview
Good Pharmacovigilance Practice Training is the essential foundation for professionals responsible for monitoring the safety of pharmaceutical products throughout their lifecycle. Pharmacovigilance is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. This guide provides a comprehensive overview of GVP training requirements and the programs available to help you stay compliant with global regulatory standards.
Why GVP Training is Essential for Pharmacovigilance Compliance
GVP Training is critical for ensuring the ongoing safety of pharmaceutical products after they reach the market. Key reasons why GVP training is essential include:
- Protecting Patient Safety – identifying and managing risks associated with drug use
- Ensuring Regulatory Compliance – meeting requirements of FDA, EMA, Health Canada, and other agencies
- Maintaining Public Trust – demonstrating commitment to drug safety and transparency
- Supporting Risk Management – implementing effective pharmacovigilance systems
- Facilitating Global Drug Safety – enabling consistent safety monitoring across jurisdictions
Key Regulatory Frameworks Covered in GVP Training
Comprehensive GVP Training covers multiple regulatory frameworks, including:
- ICH E2 Series – E2A (Clinical Safety Data Management), E2B(R3) (ICSR Data Elements), E2C(R2) (Periodic Benefit-Risk Evaluation Report), E2D (Post-Approval Safety Data), E2E (Pharmacovigilance Planning), and E2F (Development Safety Update Report)
- EU GVP Modules – European Medicines Agency guidelines for pharmacovigilance systems
- FDA Regulations – 21 CFR Parts 312 and 314 for adverse event reporting
- Canadian GVP Guidelines – Health Canada requirements for drug safety monitoring
- MedDRA Coding Standards – the international standard for coding adverse events
Detailed Course Breakdown
Course 1: Global Pharmacovigilance and Safety Reporting
This training program provides a comprehensive and detailed understanding of global regulatory requirements for pharmacovigilance, including adverse event reporting, signal detection, risk management, and periodic safety reporting.
Scope: The program integrates requirements from major regulatory bodies, including the FDA (21 CFR Parts 312 and 314), ICH guidelines (E2A, E2B(R3), E2C(R2), E2D(R1), E2E, E2F), EU GVP modules, Canadian GVP guidelines, and MedDRA coding standards. This program emphasizes practical application through detailed case studies.
Description of Modules: The curriculum covers:
- Introduction to Pharmacovigilance and its importance in drug safety
- Adverse Event Reporting – definitions and classifications including adverse events, adverse drug reactions, serious adverse events, and unexpected adverse reactions
- Expedited Reporting – 7-day and 15-day reporting requirements for individual case safety reports (ICSRs)
- Periodic Safety Reports – PSURs, PBRERs, and DSURs
- Signal Detection and risk management planning using ICH E2E principles
- MedDRA Coding and Standardised MedDRA Queries (SMQs)
- Pharmacovigilance System establishment including written procedures, training, and recordkeeping
Target Audience:
- Pharmacovigilance and Drug Safety Professionals
- Clinical Research Associates and Clinical Trial Monitors
- Regulatory Affairs Specialists
- Quality Assurance Personnel in Pharmaceutical Companies
- Medical Affairs Professionals
- Contract Research Organization (CRO) Staff
- Marketing Authorization Holders (MAHs) and their representatives
Pricing: $349.00 with group discounts available.
FAQ:
- What is the difference between an adverse event and an adverse drug reaction? An adverse event is any untoward medical occurrence in a patient, while an adverse drug reaction is a causal relationship between the drug and the event is at least a reasonable possibility.
- What is the difference between a 7-day and a 15-day safety report? A 7-day alert report is required for fatal or life-threatening unexpected serious adverse reactions, while a 15-day report is required for all other unexpected serious adverse reactions.
- What is MedDRA and why is it important? MedDRA (Medical Dictionary for Regulatory Activities) is the international standard for coding adverse events, enabling consistent safety data exchange globally.
- What is a PBRER? A PBRER (Periodic Benefit-Risk Evaluation Report) is a comprehensive safety report submitted at regular intervals after drug approval.
- What are the ICH E2 guidelines? The ICH E2 series provides guidelines for clinical safety data management, including adverse event reporting, ICSR data elements, periodic safety reports, and pharmacovigilance planning.
Enroll Now: https://www.gxptrainings.com/courses/global-pharmacovigilance-and-safety-reporting/
Course 2: GCP Global Auditor Certification Program
This training program defines the complete knowledge and performance requirements for personnel involved in clinical research to become certified global auditors for Good Clinical Practice (GCP).
Scope: The program integrates GCP requirements from ICH E6(R3), Health Canada Part C, Division 5 of the Food and Drug Regulations, and FDA regulations (21 CFR Parts 50, 56, 312, 314.50, and 314.80) with auditing practices based on ISO 19011:2026. The participant learns what GCP requires under multiple regulatory frameworks, how to audit those requirements, and how to conduct audits across multiple jurisdictions.
Description of Modules: The curriculum covers:
- Regulatory Frameworks including ICH E6(R3), Health Canada Division 5, and FDA 21 CFR Parts 50, 56, 312, 314
- Auditing Practices based on ISO 19011:2026 including seven auditing principles
- Audit programme management including objectives, risks, resources, procedures, implementation, monitoring, review, and improvement
- Conducting an audit from initiation, preparation, execution, reporting, to follow-up
- Remote auditing methods including virtual audits, technology considerations, security, and contingency planning
- Competence and evaluation of auditors including personal behaviour, knowledge and skills, evaluation methods, and maintaining competence
Target Audience:
- Quality Assurance Personnel
- Clinical Research Associates (Monitors)
- Study Directors and Clinical Trial Managers
- Clinical Investigators and Site Staff
- Sponsor Personnel
- CRO Personnel
- IRB/IEC Members and Coordinators
- Data Management and Biostatistics Professionals
- Pharmacovigilance and Safety Specialists
- Regulatory Affairs Professionals
- Audit Program Managers
Pricing: $499.00 with group discounts available.
FAQ:
- What is the difference between GCP and GVP auditing? GCP auditing focuses on clinical trial conduct and data integrity, while GVP auditing focuses on drug safety monitoring and pharmacovigilance systems.
- What are the seven principles of auditing? The seven principles are integrity, fair presentation, due professional care, confidentiality, independence, evidence-based approach, and risk-based approach.
- What is ISO 19011:2026 and why is it important for auditors? ISO 19011:2026 provides guidelines for auditing management systems, covering audit principles, programme management, conduct, remote methods, and competence evaluation.
- What is remote auditing? Remote auditing uses virtual methods and technology to conduct audits, particularly useful for global pharmacovigilance activities.
- What is the role of an auditor in pharmacovigilance? Auditors assess compliance with pharmacovigilance regulations, identify non-conformities, and verify corrective actions.
Enroll Now: https://www.gxptrainings.com/courses/gcp-global-auditor-certification-program/
Course 3: Good Clinical Practices (ICH E6(R3) Focused)
This comprehensive training program provides an in-depth exploration of the ICH E6(R3) Good Clinical Practice guideline, the globally recognized standard for the ethical and scientific quality of clinical trial design, conduct, and reporting.
Scope: Finalized in January 2025, this latest revision represents a significant modernization of GCP principles, emphasizing a risk-based, proportionate approach to trial management and the integration of digital technologies. The curriculum is structured to guide participants through the entire guideline, covering the 11 fundamental principles, the expanded roles and responsibilities of sponsors and investigators, rigorous data governance frameworks, and the critical requirements for essential records.
Description of Modules: The curriculum covers:
- ICH E6(R3) overview and its significance in global clinical research
- 11 Fundamental Principles of GCP and their application
- Sponsor responsibilities including oversight and quality management
- Investigator responsibilities including delegation and supervision
- Informed consent requirements and documentation
- Data governance and integrity frameworks
- Essential records and Trial Master File requirements
- Safety reporting and pharmacovigilance obligations
- Risk-based approaches to trial management
- Digital technologies and decentralized trial elements
Target Audience:
- Clinical Investigators and Sub-Investigators
- Sponsor Personnel (Medical, Regulatory, Clinical Operations)
- Clinical Research Associates (Monitors)
- IRB/IEC Members and Coordinators
- Data Management and Biostatistics Professionals
- Quality Assurance and Compliance Staff
- Clinical Trial Coordinators and Site Staff
- Pharmacovigilance and Safety Specialists
- Regulatory Affairs Professionals
- Clinical Research Organization (CRO) Personnel
Pricing: $149.00 with group discounts available.
FAQ:
- How does ICH E6(R3) training support pharmacovigilance? It provides the foundation for understanding safety reporting obligations and data governance requirements.
- What is the relationship between ICH E6(R3) and ICH E2? ICH E6(R3) provides the overall framework for clinical trials, while ICH E2 provides specific guidance on safety data management.
- What are the 11 fundamental principles of GCP? The 11 fundamental principles cover the ethical and scientific foundation of clinical trials, including participant safety, data integrity, and quality management.
- Why is ICH E6(R3) considered a modernization of GCP? It emphasizes risk-based, proportionate approaches and integrates digital technologies.
- Is ICH E6(R3) training mandatory for clinical trial personnel? Yes, ICH E6(R3) is the global standard for GCP, and training on this guideline is mandatory for all personnel involved in clinical research.
Enroll Now: https://www.gxptrainings.com/courses/ich-e6r3-good-clinical-practices-gcp/
Course 4: HIPAA Clinical Data Privacy, Security & Compliance Training
This training program provides organizations and individuals with a comprehensive understanding of the legal, regulatory, and operational requirements for protecting health information in clinical research and healthcare delivery settings.
Scope: The program covers the full spectrum of privacy, security, and compliance obligations under U.S. federal law and international good practice standards. It includes protection of Protected Health Information (PHI) and Electronic Protected Health Information (ePHI), HIPAA Privacy, Security, and Breach Notification Rules, Good Clinical Practice (GCP) under ICH E6(R3), and security controls for information systems.
Description of Modules: The curriculum covers 10 comprehensive sections:
- HIPAA Overview and regulatory landscape
- HIPAA Privacy Rule requirements and PHI protections
- HIPAA Security Rule requirements and ePHI safeguards
- HIPAA Breach Notification Rule requirements
- GCP and clinical data integrity requirements
- Security controls for information systems and cloud environments
- Regulatory compliance frameworks including FDA, NIST, and ISO
- Incident management and breach response
- Risk assessment methodologies
- Roles and responsibilities of Sponsors, CROs, Investigators, and technology vendors
Target Audience:
- Covered Entities under HIPAA
- Business Associates and their subcontractors
- Clinical Research Professionals, including Sponsors, CROs, Principal Investigators, and IRBs
- Security and Compliance Professionals, including Privacy Officers, Security Officials, Compliance Officers, and Risk Managers
Pricing: $249.00 with group discounts available.
FAQ:
- How does HIPAA training support pharmacovigilance? Pharmacovigilance professionals must protect patient privacy when handling safety data, making HIPAA training essential.
- What is the difference between PHI and ePHI? PHI (Protected Health Information) is health information that identifies an individual, while ePHI is PHI that is created, stored, or transmitted electronically.
- What is the HIPAA Breach Notification Rule? It requires covered entities and business associates to notify affected individuals, the HHS, and in some cases the media, following a breach of unsecured PHI.
- What is the role of a Business Associate under HIPAA? A Business Associate is a person or entity that performs certain functions or activities involving PHI on behalf of a covered entity.
- How often should HIPAA training be renewed? It is recommended to complete HIPAA training annually to stay current with regulatory updates and enforcement trends.
Enroll Now: https://www.gxptrainings.com/courses/hipaa-clinical-data-privacy-security-compliance-training/
Additional GCP Training Resources
For professionals seeking to expand their knowledge of Good Clinical Practice, we offer a comprehensive range of GCP training programs covering various aspects of clinical research compliance.
Explore Our GCP Training Category: https://www.gxptrainings.com/course-category/gcp-training/
Get Your Team Offer
For organizations looking to enroll multiple participants, we offer specialized team packages and volume discounts. Please reach out to our partnership team to discuss your specific needs and scores.
Contact Us: https://www.gxptrainings.com/contact-us/
Authors
